Vikram Purohit
Stock Analyst at Morgan Stanley
(1.82)
# 3,330
Out of 5,090 analysts
160
Total ratings
34.38%
Success rate
-8.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $5.83 | +88.68% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $39.99 | -14.98% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $63.64 | +24.14% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.53 | +66.86% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.72 | +6.04% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $206.85 | +20.86% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $103.48 | -37.19% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $149.40 | +27.18% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.43 | +103.16% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $31.74 | -2.33% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $113.65 | -85.92% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $31.03 | -67.77% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $8.66 | -30.68% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $13.05 | +221.84% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $65.79 | -37.68% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $10.97 | +264.80% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.37 | +449.68% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $17.71 | +114.57% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $9.24 | +116.57% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $18.66 | -46.41% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.10 | +1,909.13% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $13.29 | +50.45% | 2 | Aug 5, 2020 |
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $5.83
Upside: +88.68%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $39.99
Upside: -14.98%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $63.64
Upside: +24.14%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.53
Upside: +66.86%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.72
Upside: +6.04%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $206.85
Upside: +20.86%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $103.48
Upside: -37.19%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $149.40
Upside: +27.18%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.43
Upside: +103.16%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $31.74
Upside: -2.33%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $113.65
Upside: -85.92%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $31.03
Upside: -67.77%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $8.66
Upside: -30.68%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $13.05
Upside: +221.84%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $65.79
Upside: -37.68%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $10.97
Upside: +264.80%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.37
Upside: +449.68%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $17.71
Upside: +114.57%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $9.24
Upside: +116.57%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $18.66
Upside: -46.41%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.10
Upside: +1,909.13%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $13.29
Upside: +50.45%